PRESENTATION

Q1 2024 — Earnings presentation

Q1 2024PDF · 28 pages1.6 MB
2024 First Quarter Earnings
(unaudited)
Mike Roman
Chairman of the Board and
Chief Executive Officer
Monish Patolawala
President and Chief
Financial Officer
Bruce Jermeland
Senior Vice President,
Investor Relations

-- 1 of 28 --

2
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Note on non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. Refer to 3M’s April 30, 2024, press release for descriptions of non-GAAP financial measures such as adjusted net
sales (and adjusted sales change); adjusted purchases of property, plant and equipment (also referred to as adjusted capital expenditures); adjusted net cash provided by (used in)
operating activities; adjusted free cash flow; adjusted free cash flow conversion; net debt; adjusted EBITDA (and adjusted EBITDA margin); and various measures that adjust for the
impacts of special items. This presentation also includes certain preliminary estimated information that is illustrative as if 3M’s Health Care business’s (Solventum’s) net income was
reflected as a discontinued operation and further adjusted for special items. These non-GAAP measures are not in accordance with, nor are they a substitute for, GAAP measures.
Further information and reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in that press release.
This presentation contains forward-looking statements. You can identify these statements by the use of words such as “plan,” “expect,” “aim,” “believe,” “project,” “target,” “anticipate,”
“intend,” “estimate,” “will,” “should,” “could,” “would,” “forecast” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially are
the following: (1) worldwide economic, political, regulatory, international trade, geopolitical, capital markets and other external conditions and other factors beyond the Company’s
control, including inflation, recession, military conflicts, and natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2)
foreign currency exchange rates and fluctuations in those rates; (3) liabilities and the outcome of contingencies related to certain fluorochemicals known as “PFAS,” including liabilities
related to claims, lawsuits, and government regulatory proceedings concerning various PFAS-related products and chemistries, as well as risks related to the Company’s plans to exit
PFAS manufacturing and discontinue use of PFAS across its product portfolio; (4) risks related to the class-action settlement to resolve claims by public water systems in the United
States regarding PFAS; (5) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company’s reports on Form
10-K, 10-Q, and 8-K (the “Reports”); (6) competitive conditions and customer preferences; (7) the timing and market acceptance of new product and service offerings; (8) the availability
and cost of purchased components, compounds, raw materials and energy due to shortages, increased demand and wages, supply chain interruptions, or natural or other disasters; (9)
unanticipated problems or delays with the phased implementation of a global enterprise resource planning system, or security breaches and other disruptions to the Company’s
information technology infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures, and other strategic events resulting from portfolio management actions and other
evolving business strategies; (11) operational execution, including the extent to which the Company can realize the benefits of planned productivity improvements, as well as the impact
of organizational restructuring activities; (12) financial market risks that may affect the Company’s funding obligations under defined benefit pension and postretirement plans; (13) the
Company’s credit ratings and its cost of capital; (14) tax-related external conditions, including changes in tax rates, laws, or regulations; (15) matters relating to the spin-off of the
Company’s Health Care business, including the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated amounts; potential
business disruption; the diversion of management time; the impact of the transaction on the Company’s ability to retain talent; potential impacts on the Company’s relationships with its
customers, suppliers, employees, regulators and other counterparties; the ability to realize the desired tax treatment; the risk that any consents or approvals required will not be
obtained; risks under the agreements and obligations entered into in connection with the spin-off, and (16) matters relating to Combat Arms Earplugs (“CAE”), including those related to
the August 2023 settlement that is intended to resolve, to the fullest extent possible, all litigation and alleged claims involving the CAE sold or manufactured by the Company’s
subsidiary Aearo Technologies and certain of its affiliates and/or the Company. Changes in such assumptions or factors could produce significantly different results. A further
description of these factors is located in the Reports under “Cautionary Note Concerning Factors That May Affect Future Results” and “Risk Factors” in Part I, Items 1 and 1A (Annual
Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Reports). The Company assumes no obligation to update any forward-looking statements discussed herein as a result of new
information or future events or developments.
Forward-looking statements

-- 2 of 28 --

3
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Q1 2024 actuals and full-year earnings outlook approach
• Q1 2024 results are reported inclusive of the Health Care business segment, on the same basis
on which 3M provided its first-quarter guidance
– Solventum Corporation’s financial reporting will differ from the basis of presentation used by 3M for the
Health Care segment
• Full-year 2024 earnings guidance initiated today is on a continuing operations basis, reflecting
Solventum as discontinued operations for the full year, including the first quarter of 2024
– Treating changes in value of 19.9% equity interest in Solventum as an adjustment in arriving at non-GAAP
adjusted results
• Planned upcoming additional information on continuing operations basis:
– Late July/early August - Form 8-K(s) with recast 2023 Form 10-K and Q1 2024 Form 10-Q

-- 3 of 28 --

4
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Financial reporting framework
Business Groups
Adjusted
Net Sales Adjusted Operating
Income/(Loss)
Safety & Industrial X X
Transportation & Electronics X X
Health Care X X
Consumer X X
Corporate & Unallocated NA X
Total X X
Pre-spin framework Post-spin framework
(a) Beginning in April 2024, business group operating income will include the impact of dis-synergies, or stranded costs, previously associated with Solventum.
(b) “Other” includes costs previously associated with Solventum for which reimbursement to 3M begins in April 2024 (Transition Service Agreements).
(c) “Corporate & Unallocated” (Other corporate (expense) income – net) includes allocation of Q1 2024 pre-spin portion of dis-synergies, commercial agreements
with Solventum beginning in April 2024, as well as other ongoing items.
Business Groups
Adjusted
Net Sales Adjusted Operating
Income/(Loss)
Safety & Industrial(a) X X
Transportation & Electronics(a) X X
Consumer(a) X X
Other(b) X X
Corporate & Unallocated(c) X X
Total X X
Primary updates, additional details in future communications

-- 4 of 28 --

5
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Strong execution, significant progress on priorities
Driving performance
through the 3M model
Spinning off
Health Care
Reducing risk and
uncertainty
• Adjusted revenue of $7.7B,
improved organic growth
• Delivered adjusted OI margin of
21.9%, up 400 basis points YoY
• Adjusted EPS of $2.39, up
double-digits YoY
• $0.8B of adjusted free cash flow;
remain focused on working
capital improvement
• Successfully completed the spin
of Solventum on April 1st
• 3M shareholders received 80.1%
of Solventum shares
• 3M received $7.7B in cash and
retained 19.9% of shares
• Creates two world-class publicly
held companies
• Public Water Suppliers (PWS)
settlement received final court
approval
• Well over 99% of eligible
Combat Arms Earplugs claimants
have chosen to participate in the
settlement
• On track to exit all PFAS
manufacturing by year-end 2025

-- 5 of 28 --

6
2024 Q1 Earnings | April 30, 2024. All rights reserved.
• Strong operational execution and spending discipline, benefits from restructuring actions
• Significant operating leverage, particularly in Transportation and Electronics driven by
strong organic volume growth in electronics and automotive businesses
Strong operational execution drives Q1 results
Adjusted Operating
Margin of 21.9%;
Adjusted EPS of $2.39
Adjusted Free Cash
Flow of $0.8B
• Adj. organic growth of 0.8%, includes ~1.6 ppt YoY headwind from product portfolio
initiatives, disposable respirator comp, and exit of small countries
• Strength in automotive and electronics – gained share with spec-in wins and new product
introductions; strong volume growth supporting customer production and product launches
• Industrial end-markets mixed; consumer retail discretionary spending muted
• Adjusted free cash flow conversion of 63%, in-line with historical trends
• Remain focused on working capital improvement
• Continuing to invest in growth, productivity, and sustainability
Adjusted Sales
of $7.7B

-- 6 of 28 --

7
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Q1 2024 operating margin and EPS
(Includes Health Care)
Adjusted
operating
margin
Adjusted
earnings
per share Q1 YoY commentary Results vs.
Q1 guidance
Q1 2023 17.9% $1.97
Total organic growth/
productivity/other +5.5% +$0.65
Organic growth/
productivity/other +3.4% +$0.42 • Benefits from productivity, sourcing actions, restructuring, and spending
discipline, partially offset by growth, productivity, and sustainability investments • Better
Stock-based compensation
grants +1.4% +$0.15 • As disclosed in Form 10-K and factored into Q1 guidance, stock-based
compensation grants to be incurred in Q2 2024 vs. Q1 2023 due to Solventum spin • In-line
Nonrecurring items +0.7% +$0.08 • Nonrecurring items including gain on property sales • Better
Restructuring & related charges -0.9% -$0.10 • Accelerated restructuring actions
• Q1 2024 pre-tax charge of $122M versus $52M in Q1 2023 • Higher
FX -0.6% -$0.09 • Stronger U.S. dollar • Higher
Acquisition 0.0% +$0.01 • Aearo Technologies reconsolidation • In-line
Other expense/income NA +$0.05 • Primarily net interest income, partially offset by non-op pension • In-line
Tax rate* NA -$0.09 • Q1 2024 adjusted tax rate of 20.5% versus 17.7% in Q1 2023 • In-line
Shares outstanding NA -$0.01 • Average diluted shares up YoY • In-line
Q1 2024 21.9% $2.39
* The effect of income taxes on items that had specific tax rates are reflected within their respective impacts in the table above.

-- 7 of 28 --

8
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Adjusted free cash flow
$0.8B
Adjusted free cash flow
conversion
63%
Cash returned to
shareholders
$0.9B
Adjusted free cash flow • Q1: $0.8B, down 12% YoY
Adjusted free cash flow
conversion
• Q1: 63%, down 24 ppts YoY
– Continued improvement in working capital efficiency
– Higher YoY annual incentive cash compensation
Adjusted capital
expenditures
• Q1: $355M, down 20% YoY, nearing completion of water filtration
investments at manufacturing facilities
Net debt • Q1: $10.4B, down 13% YoY
Capital returned to
shareholders • Q1: dividends $0.8B
Q1 2024 cash flow and balance sheet

-- 8 of 28 --

2024 Q1 Earnings | April 30, 2024. All rights reserved.
Business Group performance
Safety &
Industrial
Transportation &
Electronics Consumer

-- 9 of 28 --

10
2024 Q1 Earnings | April 30, 2024. All rights reserved.
• Organic growth performance:
– Mid-teens increase in roofing granules; low-single digit increase in industrial
adhesives and tapes
– Low-single digit decline in electrical markets, abrasives, automotive
aftermarket, and personal safety; high-single digit decline in industrial
specialties
– Disposable respirator YoY headwind of ~$25M; reduced segment organic
growth by 80 bps
• Adjusted operating margin up 410 bps YoY; up 460 bps sequentially
– YoY increase driven by:
▪ Benefits from productivity actions, restructuring, strong spending
discipline, and stock-based compensation grants to be incurred in Q2
2024 vs. Q1 2023
▪ Partially offset by decline in organic sales volume and restructuring costs
Q1 2024 commentary
Organic growth
-1.4%
Includes ~(80) bps headwind from disposable
respirator decline
Adjusted operating margin
24.3%
Safety & Industrial

-- 10 of 28 --

11
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Q1 2024 commentary
• Adjusted organic growth performance
– Mid-teens increase in electronics; mid-single digit increase in automotive
and aerospace; low-single digit increase in commercial branding and
transportation; advanced materials flat
• Strong momentum in automotive electrification
• Share gains with spec-in wins and new product introductions in automotive
and consumer electronics; drove strong volume growth to support customer
production ramp and product launches
• Inventory normalization in electronics and automotive channels
• Adjusted operating margin up 960 bps YoY; up 540 bps sequentially
– YoY increase driven by:
▪ Benefits from strong leverage on organic sales volumes growth,
productivity actions, restructuring, strong spending discipline, and stock-
based compensation grants to be incurred in Q2 2024 vs. Q1 2023
▪ Partially offset by restructuring costs
Adjusted organic growth
6.7%
Adjusted operating margin
26.3%
Transportation & Electronics
11

-- 11 of 28 --

12
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Q1 2024 commentary
• Organic growth performance
– Low-single digit decline in home improvement, and consumer safety and
well-being
– Mid-single digit decline in home and auto care
– High-single digit decline in packaging and expression
• Continued softness in consumer discretionary spend; and product portfolio
and geographic prioritization headwind
• Investing in the business including supporting successful new product
launches
• Operating margin up 400 bps YoY; up 100 bps sequentially
– YoY increase driven by:
▪ Benefits from productivity actions, restructuring, portfolio initiatives,
strong spending discipline, and stock-based compensation grants to be
incurred in Q2 2024 vs. Q1 2023
▪ Partially offset by decline in organic sales volume and restructuring costs
Organic growth
-3.9%
Includes ~(2.4) ppt headwind from
portfolio/geographic prioritization
Operating margin
19.0%
Consumer

-- 12 of 28 --

2024 Q1 Earnings | April 30, 2024. All rights reserved.
2024 Outlook

-- 13 of 28 --

14
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Initiating 2024 full-year earnings guidance on a continuing
operations basis
Note: The spin-off of Solventum closed on April 1, 2024. 3M will not report its operations and historical comparative period earnings reflective of Solventum as a
discontinued operation under GAAP until it reports upon its second quarter of 2024. 3M is supplying preliminary estimated earnings information that is illustrative as
if Solventum were reflected as a discontinued operation. These amounts are subject to change and are unaudited.
Adjusted organic
sales growth
Adjusted
operating margin 18.5% to 18.9% +200 to 275 bps
(vs. illustrative 2023 mid-point of 18.7%)
Adjusted EPS from
continuing operations $5.97 to $6.12 $6.80 to $7.30
2023
illustrative
2024
guidance
-4.4%
(Includes 240 bps headwind from disposable
respirator decline and 2022 exit of Russia)
Flat to +2%
(Includes ~100+ bps headwind from
portfolio/geographic prioritization)

-- 14 of 28 --

15
2024 Q1 Earnings | April 30, 2024. All rights reserved.
2024 key assumptions on a continuing operations basis
(adjusted basis)
Additional full-year key assumptions:
• Total sales: ~(0.25%) to 1.75% (~49% H1/51% H2)
• Acquisition/divestiture: ~0.75% (revenue from Solventum agreements)
• Foreign currency: sales translation of ~(1%), and earnings per share of ~($0.20)
• Operating income (~47% H1/53% H2)
• Pre-tax restructuring charges: ~$250M to $300M (~70% H1/30% H2)
• Increased investments in growth, productivity, and sustainability
• Other expense, net: ~$75M to $100M (~10% H1/90% H2)
• Tax rate: 19% to 20% (~20% H1/19% H2)
• EPS: $6.80 to $7.30 (~47% H1/53% H2)
Q1 2024
illustrative
Sales ~$5.7B
Operating
income
margin rate
~$1.2B
~21.1% to 21.5%
Other
expense, net ~$16M
Tax rate ~20.9%
Earnings
per share ~$1.69 to $1.73
Note: The spin-off of Solventum closed on April 1, 2024. 3M will not report its operations and historical comparative period earnings reflective of Solventum as a
discontinued operation under GAAP until it reports upon its second quarter of 2024. 3M is supplying preliminary estimated earnings information that is illustrative as
if Solventum were reflected as a discontinued operation. These amounts are subject to change and are unaudited.

-- 15 of 28 --

16
2024 Q1 Earnings | April 30, 2024. All rights reserved.
2024 business group outlook
• Organic sales growth:
down LSD
• Portfolio/geographic
prioritization sales headwind
of ~2 ppts
• Consumer discretionary
spending muted
• Adjusted organic sales growth:
up LSD
• Auto build forecast slightly
negative (IHS)
• Consumer electronics
demand up slightly
• Continued strong auto
electrification growth
• Organic sales growth:
flat to up LSD
• Industrial end-market
demand mixed
• Industrial Production Index
(IPI) up ~2% (IHS)
Safety &
Industrial
Transportation &
Electronics Consumer

-- 16 of 28 --

17
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Resetting our dividend post Solventum spin
• 100+ year history of paying shareholders a competitive dividend
• Distributed 80.1% of Solventum’s outstanding shares to 3M shareholders
• Following the spin of Solventum, 3M’s dividend payout ratio is expected to be approximately
40% of adjusted free cash flow with potential to increase over time
• Dividend payout in-line with industrial peers and well above S&P 500 median
• Second quarter dividend expected to be declared in May 2024, subject to board approval
• Share repurchases – stepped back into the market

-- 17 of 28 --

18
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Closing comments
• Q1 a strong start to the year
• Delivering on our priorities … strong operational execution driving improved financial
performance and completed major milestones
• Remain focused on delivering for our customers and shareholders; our strategies have
positioned the company for long-term value creation
• Welcome Bill Brown as next 3M CEO effective May 1st

-- 18 of 28 --

2024 Q1 Earnings | April 30, 2024. All rights reserved.
Q&A Mike Roman
Chairman of the Board and
Chief Executive Officer
Monish Patolawala
President and
Chief Financial Officer
Bruce Jermeland
Senior Vice President,
Investor Relations

-- 19 of 28 --

2024 Q1 Earnings | April 30, 2024. All rights reserved.
Appendix

-- 20 of 28 --

21
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Q1 2024 P&L
GAAP ($M), except per share
amounts
Q1
2024
Q1
2023 Change
Sales $8,003 $8,031 (0.3)%
Gross profit $3,674 $3,418 7.5%
% to sales 45.9% 42.6% 3.3%
SG&A $1,736 $1,705 1.8%
% to sales 21.6% 21.3% 0.3%
R&D & related $437 $472 (7.4)%
% to sales 5.5% 5.9% (0.4)%
Operating income $1,501 $1,241 20.9%
% to sales 18.8% 15.4% 3.4%
Net income $928 $976 (5.0)%
Earnings per share $1.67 $1.76 (5.4)%

-- 21 of 28 --

22
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Q1 2024 adjusted sales recap
Americas EMEA APAC Worldwide
Organic growth (0.9)% 3.3% 2.6% 0.8%
Acquisitions/divestitures 0.6% (0.2)% —% 0.3%
FX 0.4% 1.7% (4.3)% (0.6)%
Total growth 0.1% 4.8% (1.7)% 0.5%

-- 22 of 28 --

23
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Q1 2024 business segment information
*"Safety & Industrial", "Transportation & Electronics", "Corporate & Unallocated", "Total Operating Business Segment" and "Total" provided on an adjusted basis while
“Health Care” and “Consumer” are not provided on an adjusted basis
($M) Adjusted net sales* Q1 2024 adjusted sales growth* Adjusted operating income* Adjusted operating margin*
Business Groups
Q1
2024
Q1
2023
Organic
growth FX M&A
Total
sales
change
Q1
2024
Q1
2023 Percent
change
Q1
2024
Q1
2023
Safety & Industrial $2,732 $2,779 (1.4)% (0.3)% —% (1.7)% $664 $562 18.2% 24.3% 20.2%
Transportation & Electronics $1,823 $1,705 6.7% (1.5)% 1.7% 6.9% $479 $284 68.5% 26.3% 16.7%
Health Care $2,017 $2,010 1.0% (0.4)% (0.3)% 0.3% $354 $360 (1.6)% 17.5% 17.9%
Consumer $1,140 $1,192 (3.9)% (0.4)% —% (4.3)% $216 $179 20.9% 19.0% 15.0%
Total Operating Business
Segment $7,712 $7,686 $1,713 $1,385
Corporate & Unallocated $10 $— $(23) $(9)
Total $7,722 $7,686 0.8% (0.6)% 0.3% 0.5% $1,690 $1,376 22.8% 21.9% 17.9%

-- 23 of 28 --

24
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Q1 2024 commentary
• Organic growth performance
– Mid-single digit increase in purification and filtration
– Medical surgical (MedSurg), dental solutions, and health information
systems flat
• Operating margin down 40 bps YoY; down 80 bps sequentially
Organic growth
1.0%
Operating margin
17.5%
Health Care

-- 24 of 28 --

25
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Additional GAAP sales detail
($M) GAAP Net Sales
Business Groups Q1 2024 Q1 2023
Abrasives 328 341
Automotive Aftermarket 306 312
Electrical Markets 311 324
Industrial Adhesives and Tapes 518 516
Industrial Specialties Division 284 308
Personal Safety 857 868
Roofing Granules 128 110
Total Safety & Industrial Business Group 2,732 2,779
Advanced Materials 263 301
Automotive and Aerospace 506 462
Commercial Branding & Transportation 610 615
Electronics 725 672
Total Transportation & Electronics Business Group 2,104 2,050
($M) GAAP Net Sales
Business Groups Q1 2024 Q1 2023
Health Information Systems 300 300
Medical Surgical (MedSurg) 1,123 1,123
Dental Solutions 335 341
Purification and Filtration 245 232
Other Health Care 14 14
Total Health Care Business Group 2,017 2,010
Consumer Safety and Well-Being 266 270
Home and Auto Care 305 318
Home Improvement 330 341
Packaging and Expression 239 263
Total Consumer Business Group 1,140 1,192
Corporate and Unallocated 10 —
Total 3M 8,003 8,031

-- 25 of 28 --

26
2024 Q1 Earnings | April 30, 2024. All rights reserved.
“Other” category and “Corporate & Unallocated” details
($ in millions) Other(a)
Q1 2024
illustrative
Remaining
Q2 - Q4 2024
FY 2024
estimated
Net operating
income/(loss) ~($65) ~$40 to $65 ~Flat to ($25)
Note: The spin-off of Solventum closed on April 1, 2024. 3M will not report its operations and historical comparative period earnings reflective of Solventum as a
discontinued operation under GAAP until it reports upon its second quarter of 2024. 3M is supplying preliminary estimated earnings information that is illustrative as
if Solventum were reflected as a discontinued operation. These amounts are subject to change and are unaudited.
($ in millions) Corporate & Unallocated(b)
Q1 2024
illustrative
Remaining
Q2 - Q4 2024
FY 2024
estimated
Sales ~$25 ~$200 to $250 ~$225 to $275
Net operating
income/(loss) ~($75) ~($50 to $100) ~($125 to $175)
(a) “Other” includes costs previously associated with Solventum for which reimbursement to 3M begins in April 2024 (Transition Service Agreements).
(b) “Corporate & Unallocated” (Other corporate (expense) income – net) includes allocation of Q1 2024 pre-spin portion of dis-synergies, commercial
agreements with Solventum beginning in April 2024, as well as other ongoing items.

-- 26 of 28 --

27
2024 Q1 Earnings | April 30, 2024. All rights reserved.
Our 2024 priorities: Reduce risk and uncertainty
• Public Water Suppliers (PWS) settlement received final court approval
• Agreement includes pre-tax present value commitment of up to $10.3B payable over 13 years
• Supports PFAS remediation for U.S. PWS that have or may detect in the future any form of PFAS at any level
• Combat Arms Earplugs settlement moves to final resolution
• Pre-tax present value of $5.3B payable over 7 years
• Well over 99% of eligible Combat Arms Earplugs claimants have chosen to participate in the settlement
• Anticipate the settlement will achieve a more than 99.9% participation level
• Estimated total combined pre-tax present value of $15.6B, or ~$13B after-tax
• Actively engaged in insurance recovery activities
Pre-tax
payments ($B) 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Total
PFAS PWS* $0.1 $2.9 $1.8 $0.4 $2.6 $1.6 $0.6 $0.6 $0.6 $0.5 $0.4 $0.2 $0.2 $0.2 $12.5
Combat Arms $0.4 $1.4 $1.5 $1.4 $0.8 $0.3 $0.3 - - - - - - - $6.0
Total $0.5 $4.3 $3.3 $1.8 $3.4 $1.9 $0.9 $0.6 $0.6 $0.5 $0.4 $0.2 $0.2 $0.2 $18.5
* Expected pre-tax payments assuming the nominal $12.5B settlement cap is reached.

-- 27 of 28 --



-- 28 of 28 --